Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1

Conditions

Sarcoma 3Glioblastoma 3Small Cell Lung Carcinoma 1Recurrence 1Prostatic Neoplasms 1Leukemia, Myeloid, Acute 1Leiomyosarcoma 1Ichthyosis, X-Linked 1Glioma 1Carcinoma, Non-Small-Cell Lung 1Carcinoma, Hepatocellular 1

Interventions

Carboplatin 47Etoposide 46durvalumab 28atezolizumab 28Cisplatin 21Topotecan 19pembrolizumab 15PM 01183 15Nivolumab 12Specimen Handling 11anlotinib 9Radiotherapy 9Paclitaxel 9Drug Therapy 9Temozolomide 8Magnetic Resonance Spectroscopy 8AMG 757 8Radiosurgery 7Platinum 7Irinotecan 7toripalimab 6olaparib 6Biopsy 6Ipilimumab 5Injections 5Docetaxel 5Bevacizumab 5trilaciclib 4tremelimumab 4tislelizumab 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Small Cell Lung Carcinoma × ADI PEG20 × 1 year × Clear all
NCT05616624 2026-04-15

ADI-PEG 20 in Combination With Gemcitabine and Docetaxel After Progression on Frontline Therapy in Non-small Cell and Small Cell Lung Cancers

Washington University School of Medicine

Phase 1/2 Active not recruiting
31 enrolled
Thoracic

Carcinoma, Non-Small-Cell Lung, Small Cell Lung Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡